NIH awards Phase I SBIR grant to DNA Medicine Institute for emergency blood sensor

The DNA Medicine Institute, a commercial organization focused on advancing human health through innovation, today announced that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).  The grant is designed to shrink technology found in large hospital hematology analyzers, typically the size of small refrigerators, to a tiny, palm-sized device.  The emergency blood sensor is designed to make these tests readily available under any scenario and easily performed by minimally trained personnel.  Applicable settings include hospitals, emergency rooms, physicians' offices, ambulances, global health clinics, and remote field locations.  The Institute envisions this technology will be integrated into its Universal Blood Sensor platform, which is designed to perform all hospital tests on a handheld, point-of-care device.

"We are pleased that the NIH is supporting our efforts to develop a potentially transformative human diagnostics platform.  The NHLBI understands the human impact of a point-of-care blood sensor that can diagnose acute blood loss, sepsis, and other critical health conditions," said Eugene Y. Chan, M.D., President and Chief Scientific Officer of the DNA Medicine Institute.  "This funding will allow us to further innovations in the point-of-care diagnostics field and speed development of a technology that can be utilized to make a difference for those in need."

SOURCE DNA Medicine Institute